Resources

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

• External Link

Results of the Pivotal STORM Study (Part 2): Deep and Durable Responses with Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Exposed and Triple Class Refractory MM

• PDF (977.89 KB)

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome(SDd) in Patients with Multiple Myeloma Previously Treated with PIs and IMiDs: Results of Phase 1b/2 Study of SDd

• PDF (521.56 KB)

Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

• PDF (1.45 MB)

Selinexor, a First-in-Class XP01 Inhibitor, is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes (MDS) Refractory to Hypomethylating Agents

• PDF (1.32 MB)

Phase I Trial of the Selective Inhibitor of Nuclear Export, SELINEXOR, in Relapsed Childhood Leukemia

• PDF (2.62 MB)

Final Results from a Phase I Trial Combining Selinexor with High-dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)

• PDF (333.28 KB)

Efficacy of Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma: Results of the Pivotal STORM Part II Study

• PDF (1.97 MB)

Selinexor combined with low dose bortezomib and dexamethasone (SVd) induces a high response rate in patients with relapsed or refractory multiple myeloma (MM)

• PDF (718.17 KB)

A Phase 1b study using the combination of selinexor, daratumumab, and dexamethasone in multiple myeloma patients previously exposed to proteasome inhibitors and immunomodulatory drugs

• PDF (556.14 KB)